Orphan drugs offer major opportunities, says report
Legislation over the past four years has provided opportunities for big and small companies employing deliberate or add-on orphan drug development programmes, says a new report from Urch Publishing on the growing orphan drug sector in Europe.
Legislation over the past four years has provided opportunities for big and small companies employing deliberate or add-on orphan drug development programmes, says a new report from Urch Publishing on the growing orphan drug sector in Europe.
The 155-page report, Orphan Drugs to 2008 - Understanding regulation & market opportunity in Europe, aims to help global companies to better understand the opportunities presented by recent developments in Europe orphan drug legislation.
'In the four years since orphan drug legislation has been in place, 204 projects have been granted orphan status by the European Medicines Evaluation, and of these 15 had received a successful marketing authorised by June 2004,' said Steve Seget, the report's author.
The report uses detailed regulatory, company and primary source information to provide a detailed guide to employing orphan drug development and marketing strategies in Europe, and contains detailed analysis of major orphan drugs, including Aldurazyme, Replagal and Ventavis.
It also looks at the global opportunity for orphan medicines, and outlines the European regulations and procedures in detail.